Join our daily newsletter At The Bell to receive exclusive market insights
- Consumer goods developer and manufacturer Jatcorp (JAT) has announced it has entered into a 10-year sales agreement with Nightingale PS
- The agreement will see Nightingale sell Jatcorp’s existing and future products to its own customers, which include pharmacy and supermarket chains
- Alongside the sale agreement, JAT also announced it had been approved by the South Korean regulatory authority to export its dairy products
- The company has now signed an agreement with a Korean distributor for an initial order of its products for resale
- Finally, Jatcorp also announced it has successfully developed its first A2 Ejiao Protein Powder, with plans to begin selling the product next year
- Shares in JAT are trading down 3.57 per cent at 2.7 cents each
Jatcorp (JAT) has released a wideranging business update, announcing a new sales agreement, product expansion and potential market gain.
Sales agreement
The biggest news from the consumer goods developer and manufacturer was that it has entered into a 10-year sales agreement with Nightingale PS.
Under the agreement, Nightingale will sell Jatcorp’s existing and future products to its own customers, which include pharmacy and supermarket chains across Australia and the U.K.
In return, the business will receive a commission on revenues from sales of any and all of JAT’s products.
Nightingale has stated it will first aim to sell Jatcorp’s wares to Australian supermarket chains, followed by sales to pharmacies also within the country.
The company will then focus on selling JAT products to its U.K. customers and potentially other markets outside China.
New product & market
Alongside the sales agreement, Jatcorp also announced it has successfully developed its first A2 Ejiao Protein Powder.
Ejiao is essentially a hard gel which can be dissolved in hot water or alcohol to be used in food, drink or beauty product.
The substance is currently sold throughout south-east Asia as consumers believe its helps with blood circulation.
Jatcorp’s version of the product is currently being manufactured in Melbourne, with the possibility it will be ready to be sold by early 2021.
Finally, the consumer stock also announced in today’s update that it had been approved to sell its products in Korea.
The South Korean regulatory authority has given the green light to JAT’s dairy
based nutritional products — allowing them to be exported into the country.
Following the approval, Jatcorp has begun negotiating with different Korean
companies to export in JAT’s Jinvigorate brand diabetics formula and other products.
Shares in Jatcorp are trading slightly down despite today’s update, dropping 3.57 per cent in the red to trade at 2.7 cents each at 1:22 pm AEDT.
